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Letter to the Editor
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Dear Sir:
The incidence of cerebral venous thrombosis (CVT) is on the rise,
partly due to an improvement in the diagnostic techniques.1
However, the therapeutic options have not changed much in the
past three decades. Heparin followed by vitamin K antagonist
(VKA), Warfarin is still the mainstay of treatment,2-4 although
the limitations of VKA therapy including risk of major bleeding,
need for constant monitoring, and drug and dietary interactions
are all well recognized.5,6
New direct oral anticoagulants (NOACs), which are target specific for factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin
(dabigatran), were developed to overcome some of these limitations. These drugs have already shown to be safer then VKA for
recurrent venous thromboembolism and embolism prevention in
atrial fibrillation, with fewer intracranial and extracranial hemorrhages, fewer fatal hemorrhages and no increase in the risk of
gastrointestinal hemorrhages.7 Based on this safety data, and the
efficacy results from venous thromboembolism studies, there is a
growing tendency for neurologists to consider them for treatment of CVT. A few case series have been published supporting
the safety and efficacy of these drugs in CVT cases.8-11 More re-

cently, the results of one randomized controlled trial (randomized
controlled trial of the safety and efficacy of dabigatran etexilate
vs. dose-adjusted warfarin in patients with cerebral venous
thrombosis [RESPECT CVT]) were presented at World Stroke Congress in 2018.12 The trial randomized 120 patients to either dabigatran or warfarin and showed no recurrence of venous thrombotic events and a small number of major bleedings in both arms.
Before the results of RESPECT CVT were made available, we
conducted a multicenter prospective, observational study to
evaluate the safety of NOACs compared to warfarin in patients
with CVT. Data was collected from October 2016 to October
2018. Nine centers in four countries Pakistan, Saudi Arabia,
Egypt, and the United Arab Emirates participated in the study. All
nine centers are tertiary care hospitals with full time neurologists
and availability of diagnostic modalities for the diagnosis of CVT.
We included consecutive patients aged 18 years or more, who
presented with clinical features of CVT, confirmed with venography (either computed tomography [CT] or magnetic resonance
[MR]). Those with traumatic or septic CVT were excluded. Baseline characteristics including demographics, Glasgow Coma
Scale, clinical features, imaging findings, and anticoagulant at
discharge were recorded. Choice of oral anticoagulation was left
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Table 1. NOACs vs. warfarin for cerebral venous thrombosis (n=111)
Variable
Age (yr)
Female sex

All patients (n=111)

NOACs (n=45, 41%)

Warfarin (n=66, 59%)

P

39.3±14.9

36.5±14.7

41.3±14.8

0.10

64 (57.7)

27 (60)

37 (56.1)

0.68

Predisposing factors
Pregnancy/puerperium

15 (23.1)

8 (28.6)

7 (18.9)

0.36

Hematological disorders

74 (66.7)

28 (62.2)

46 (69.7)

0.41

6 (10.5)

0.03

Malignancy

6 (5.4)

Systemic infections

36 (32.4)

Drugs/OCP

11 (9.9)

Other medical conditions

7 (6.3)

0 (0)
15 (33.3)

21 (31.8)

0.86

4 (9)

7 (11)

0.32

6 (13.3)

1 (1.5)

0.01

Clinical findings
Baseline GCS (available in 89 cases)

0.73

13–15

64 (71)

28 (74)

36 (70)

9–12

17 (19)

7 (18)

10 (20)

8 (10)

3 (8)

5 (10)

Seizures

37 (33.3)

14 (31)

23 (34.8)

0.68

Paresis

49 (44)

22 (48)

27 (52)

0.32

7 (6.3)

5 (11)

2 (3.0)

0.08

84 (75.7)

42 (93)

42 (63.6)

<0.001

4 (3.6)

1 (2)

≤8

Aphasia
Headache
Papilledema

3 (4)

0.18

Imaging findings
Intracerebral hemorrhage

45 (40.5)

25 (55.6)

20 (30.3)

0.01

Venous infarction

54 (48.6)

25 (55.6)

29 (43.9)

0.22

Midline shift

10 (9.0)

4 (8.9)

6 (9.1)

0.97

Hydrocephalus

1 (0.9)

1 (1.5)

0.40

SSS thrombus

56 (50.5)

26 (57.8)

0 (0)

30 (45.5)

0.20

TS thrombus

60 (54.1)

30 (66.7)

30 (45.5)

0.02

Straight sinus/DCVT/cortical vein

28 (25.2)

11 (24.4)

17 (25.8)

0.87

Sigmoid sinus/jugular vein

62 (55.9)

29 (64.4)

33 (50)

0.13

Heparin/LMWH

79 (71)

36 (80)

43 (65)

0.06

Surgery

12 (10.8)

5 (12.5)

7 (11.7)

6 (3–11)

7 (3–12)

5 (3–10)

Treatment

Start of oral anticoagulation in days
mRS at discharge

111

45

66

0

23 (21)

11 (25)

12 (18)

1

29 (26)

11 (23)

18 (28)

2

28 (25)

12 (27)

16 (23)

3

15 (14)

4 (9)

11 (17)

4

10 (10)

5 (10)

5 (8)

5

2 (2)

1 (2)

1 (2)

6

4 (4)

1 (2)

3 (5)
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Table 1. Continued
Variable
mRS at 6 months

All patients (n=111)

NOACs (n=45, 41%)

Warfarin (n=66, 59%)

95

39

56

0

37 (39)

17 (44)

20 (36)

1

23 (24)

8 (21)

15 (28)

2

19 (20)

10 (26)

9 (16)

3

9 (10)

2 (4)

7 (12)

4

4 (4)

1 (2)

3 (5)

5

3 (3)

1 (2)

2 (3)

6

2 (0.02)

1 (0.03)

1 (0.02)

P
0.30

Values are presented as mean±standard deviation, number (%), or median (interquartile range).
NOAC, new direct oral anticoagulant; OCP, oral contraceptive pill; GCS, Glasgow Coma Scale; SSS, superior sagittal sinus; TS, transverse sinus; DCVT, deep cerebral vein thrombosis; LMWH, low molecular weight heparin; mRS, modified Rankin Scale.

to the discretion of the treating physician. Recruited patients
were followed up prospectively for outcomes assessment which
was done by the treating physician in outpatient clinic setup.
Treating physicians took verbal consent from the patients or
their surrogates for contributing their data to the study. Ethics
approval was taken from the Institutional Review Board of
each participating center. Data was entered and analyzed on
SPSS version 21 (IBM Co., Armonk, NY, USA).
A total of 111 patients were included (45 were on NOACs
and 66 on warfarin). Diagnosis was confirmed by magnetic
resonance imaging (MRI)/magnetic resonance venography
(MRV) in 96, CT venogram in 10 and both MRV and CT venogram in five patients. Out of 45 patients on NOACs, 36 were
given rivaroxaban and nine were given dabigatran. Warfarin
was adjusted to achieve an international normalized ratio
(INR) of 2 to 3. The mean age of the participants was
39.3±14.9 years and 57% were females and the two groups
were comparable (Table 1). Hematological disorders followed
by systemic infections were the most common etiological
factors for CVT in both the NOAC and warfarin groups. Malignancy was a more common predisposing factor in the warfarin group, with six out of 66 patients suffering from the
condition. No patient in the NOAC arm had malignancy.
Whereas the two groups did not differ significantly in terms
of clinical features, patients in the NOAC group presented more
frequently with headache (93% vs. 63%) and were significantly more likely than warfarin group to have intracerebral hemorrhage on initial imaging, reflecting the comfort of treating
physician with NOACs. There were no other significant differences in the clinical and imaging features of the two groups.
Patients in both groups were started on oral anticoagulation
(warfarin with target INR 2 to 3; rivaroxaban 15 to 20 mg;
dabigatrin 75 to 150 mg twice a day) within median of one
222
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week of diagnosis. At discharge as well as at 6 months followup, the functional outcomes as measured by modified Rankin
Scale, were not significantly different between the two groups.
Four patients died during hospital stay, one in the NOAC arm
and three in the warfarin arm. The hospital course was complicated by extracranial hemorrhage in two patients, both of
whom were in the warfarin group. Two additional patients
were dead at 6 months follow-up, one in each group.
Follow-up ranged from minimum 6 to 13 months (median,
8). All patients underwent neurological examination at followup. Follow-up evaluation included history of headaches, seizures, any signs of bleeding, side effects and compliance of
medications, evaluation of modified Rankin Scale score and
any imaging. At 6 months follow-up (95/107 discharged patients, 89%), clinical neurological worsening was reported in
one patient (warfarin group), and no patient required switching
from one to the other group. In addition, no patient required
discontinuation of therapy by the physician. Only 12 patients
(five in NOAC group, seven in warfarin group) had follow-up
MRI/MRV (one patient for neurologic worsening, mostly for
persistent headache and non-improvement) during 6 months
follow-up. Of these, four in the NOAC arm and four in the warfarin arm had complete and the rest had partial recanalization.
Six patients reported systemic bleeding at follow-up, two in
the NOAC arm and four in the warfarin arm. As per International Society on Thrombosis and Haemostasis (ISTH) classification, one patient had major, one non-major clinically relevant, and four had minor hemorrhages. Only one patient in the
NOAC arm required blood transfusion and a single patient in
the warfarin group had intracranial hemorrhage that required
intervention. No recurrent thrombotic events were seen in any
of the patients.
This open label, comparative study reports on the largest cohttps://doi.org/10.5853/jos.2019.00150

Vol. 21 / No. 2 / May 2019

hort of CVT patients treated with new oral anticoagulants and
shows that the use of NOACs (mainly rivaroxaban and dabigatran) appear to be safe and may be as effective as warfarin in
patients with CVT. Limitations of our study include non-randomization, open label, lack of adequate radiological data at
follow-up to assess recanalization and non-blinded and nonadjudicated outcome assessments. Despite these, our study
findings provide external validity for the RESPECT CVT results
in a real-world setting and supports the growing trend of
NOAC use for this potentially devastating condition.
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